CIK 0001776111 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MBX Biosciences, Inc.
Sign in to watch- Ticker
- MBX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 3179893100
- Business address
- 11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,361
- in 2 filings
Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | Aynechi Tiba Director | Conversion | +1,386,335 | 1,386,335 | ||
| 2024-09-16 | Aynechi Tiba Director | Purchase | +750,000 | $16.00 | $12.0M | 2,136,335 |
| 2024-09-16 | Aynechi Tiba Director | Conversion · Series B Convertible Preferred Stock | −16,666,666 | 0 | ||
| 2024-09-16 | GORDON CARL L Director | Conversion | +2,658,428 | 2,658,428 | ||
| 2024-09-16 | GORDON CARL L Director | Conversion | +403,787 | 403,787 | ||
| 2024-09-16 | GORDON CARL L Director | Purchase | +500,000 | $16.00 | $8.0M | 3,158,428 |
| 2024-09-16 | GORDON CARL L Director | Purchase | +250,000 | $16.00 | $4.0M | 653,787 |
| 2024-09-16 | GORDON CARL L Director | Conversion · Series A Convertible Preferred Stock | −12,372,634 | 0 | ||
| 2024-09-16 | GORDON CARL L Director | Conversion · Series B Convertible Preferred Stock | −19,587,284 | 0 | ||
| 2024-09-16 | GORDON CARL L Director | Conversion · Series C Convertible Preferred Stock | −4,854,368 | 0 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion | +1,386,335 | 1,386,335 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion | +403,787 | 1,790,122 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion · Series B Preferred Stock | −16,666,666 | 0 | ||
| 2024-09-16 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% owner | Conversion · Series C Preferred Stock | −4,854,368 | 0 | ||
| 2024-09-12 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +15,963 | 15,963 | ||
| 2024-09-12 | Ryder Steven Director | Grant or award · Stock Option (Right to Buy) | +15,963 | 15,963 | ||
| 2024-09-12 | Bartram Richard Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +42,578 | 42,578 | ||
| 2024-09-12 | Azoulay Salomon Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +45,011 | 45,011 | ||
| 2024-09-12 | Mathers Edward T Director | Grant or award · Stock Option (Right to Buy) | +15,963 | 15,963 | ||
| 2024-09-12 | Hawryluk P. Kent President & CEO | Grant or award · Stock Option (Right to Buy) | +120,436 | 120,436 |
Page 8 of 9 · 164 trades